Citations

Clear

1011 citation(s) found for "Barry, WT".

Pseudo-Severe Mitral Stenosis From Obesity-Related HFpEF and Atrial Myopathy
Cao, Jenny Jia Ling , Miranda, William R. , Borlaug, Barry A. , Reddy, Yogesh N.V. , Nishimura, Rick , Borlaug, Barry A , Cao, Jenny J

Mayo Clinic

Circulation: Heart Failure | January 28, 2025 | Volume: 18 | Issue: 3 | Pages: No page available

10.1161/circheartfailure.124.012703 | PMID 39873104 Get It

Lymph Node Staging and Treatment in Pediatric Patients With Soft Tissue Sarcomas: A Consensus Opinion From the Children's Oncology Group, European paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe
Scheltinga, Sheila Terwisscha van , Kao, Simon C. , Keizer, Bart de , McCarville, M. Beth , Casey, Dana L. , Merks, Hans, Kapadia, Tejas , Walterhouse, David O., Hiemcke‐Jiwa, Laura S. , Franzius, Christiane, Vokuhl, Christian , Dasgupta, Roshni, Birz, Suzi , Rodeberg, David A. , Dasgupta, Roshni , Terwisscha van Scheltinga, Sheila , de Keizer, Bart , Shulkin, Barry L , Casey, Dana L , Allen-Rhoades, Wendy, Orbach, Daniel , Davila Fajardo, Raquel , Oberoi, Saphna , Vokuhl, Christian , Rodeberg, David A , Kao, Simon C , Dasgupta, Roshni , Schoot, Reineke A , Routh, Jonathan C. , Seitz, Guido , Shulkin, Barry L. , Ewijk, Roelof van , Allen‐Rhoades, Wendy , Mercolini, Federico , Merks, Hans, Fajardo, Raquel Dávila , Corti, Federica De , Tang, Vivian , Metts, Jonathan L.

Mayo Clinic

Pediatric Blood & Cancer | January 23, 2025 | Volume: 72 | Issue: 4 | Pages: No page available

10.1002/pbc.31538 | PMID 39844722 Get It

ABSTRACTAccurate staging of nodal involvement in pediatric sarcoma patients is important to determine correct systemic and local therapy, with the goal to reduce subsequent recurrences. However, differences in lymph node staging strategies, definitions, and treatment protocols between the Children's Oncology Group (COG), European paediatric Soft tissue sarcoma Study Group (EpSSG), and the Cooperative Weichteilsarkom Studiengruppe (CWS) complicate comparisons. In this article, we aim to establish internationally recognized recommendations for lymph node assessment and treatment of children and adolescents diagnosed with rhabdomyosarcoma (RMS) and non‐rhabdomyosarcoma soft tissue sarcoma (NRSTS) according to the Consensus Conference Standard Operating Procedure methodology.
Evidence-Based Application of Natriuretic Peptides in the Evaluation of Chronic Heart Failure With Preserved Ejection Fraction in the Ambulatory Outpatient Setting
Reddy, Yogesh N.V. , Tada, Atsushi , Obokata, Masaru , Carter, Rickey E. , Kaye, David M. , Handoko, M. Louis , Sharma, Kavita , Tedford, Ryan J. , Redfield, Margaret M. , Andersen, Mads Jønsson , Sharma, Kavita , Tedford, Ryan J , Redfield, Margaret M , Borlaug, Barry A , Nishimura, Rick , Carter, Rickey E , Kaye, David M , Obokata, Masaru , Andersen, Mads J. , Borlaug, Barry A.

Mayo Clinic

Circulation | January 22, 2025 | Volume: 151 | Issue: 14 | Pages: 976-989

10.1161/circulationaha.124.072156 | PMID 39840432 Get It

BACKGROUND: Plasma NT-proBNP (N-terminal pro-B-type natriuretic peptide) is commonly used to diagnose heart failure with preserved ejection fraction (HFpEF), but its diagnostic performance in the ambulatory/outpatient setting is unknown because previous studies lacked objective reference standards. METHODS: Among patients with chronic dyspnea, diagnosis of HFpEF or noncardiac dyspnea was determined conclusively by exercise catheterization in a derivation cohort (n=414), multicenter validation cohort 1 (n=560), validation cohort 2 (n=207), and a nonobese Japanese validation cohort 3 (n=77). Optimal NT-proBNP cut points for HFpEF rule out (optimizing sensitivity) and rule in (optimizing specificity) were derived and tested, stratified by obesity and atrial fibrillation. Derived cut points were tested in 3 additional validation cohorts (cohorts 4–6) in whom HFpEF was diagnosed by resting catheterization only (n=260), previous hospitalization for heart failure (n=447), or exercise echocardiography (n=517), respectively. RESULTS: Current recommended rule-out NT-proBNP threshold <125 pg/mL had 82% sensitivity (95% CI, 77%–88%) with a body mass index (BMI) <35 kg/m 2 , decreasing to 67% (95% CI, 58%–77%) with a BMI ≥35 kg/m 2 . A lower rule-out NT-proBNP threshold <50 pg/mL displayed good sensitivity with a BMI <35 kg/m 2 (97% [95% CI, 95%–99%]), with a modest decline in sensitivity with a BMI ≥35 kg/m 2 (86% [95% CI, 79%–93%]); diagnostic thresholds were confirmed in validation cohorts 1 and 2 (91% [95% CI, 88%–95%] and 86% [95% CI, 80%–93%] with a BMI <35 kg/m 2 ; 80% [95% CI, 74%–87%] and 84% [95% CI, 74%–93%] with a BMI ≥35 kg/m 2 ). Current consensus age- and BMI-stratified rule-in thresholds demonstrated only 65% specificity (95% CI, 57%–72%). Rule-in NT-proBNP threshold ≥500 pg/mL had 85% specificity (95% CI, 78%–91%) with a BMI <35 kg/m 2 (87% [95% CI, 80%–94%] and 90% [95% CI, 81%–99%] in validation cohorts), with 100% specificity at a BMI ≥35 kg/m 2 (93% [95% CI, 81%–100%] and 100% in validation cohorts). With a BMI ≥35 kg/m 2 , lower rule-in thresholds (≥220 pg/mL) provided good specificity (88% [95% CI, 73%–100%]; 93% [95% CI, 81%–100%] and 100% in validation cohorts). Findings were consistent in validation cohorts 3 through 6 (sensitivity of <50 pg/mL, 93%–98%; specificity of ≥500 pg/mL, 82%–89%). NT-proBNP provided no incremental discrimination among patients with history of AF; ≥98% of patients with AF and dyspnea were found to have HFpEF in our cohorts. CONCLUSIONS: In patients with chronic unexplained dyspnea, current rule-in and rule-out NT-proBNP diagnostic thresholds lead to unacceptably high error rates, with important interactions by obesity and AF status. In our study, NT-proBNP provided little value in those with AF and dyspnea because the presence of AF is by itself a robust biomarker of HFpEF. Use of separate rule-in and rule-out diagnostic thresholds stratified by BMI reduces miscategorization and can guide more appropriate use of exercise testing for possible HFpEF.
Single-Leg Supine Cycling: An alternative for Patients Requiring Exercise Catheterization and Femoral Access
Hortegal, Renato A. , Jain, C. Charles , Reddy, Yogesh N.V. , Borlaug, Barry A, Egbe, Alexander C. , Miranda, William R. , Nishimura, Rick , Borlaug, Barry A.

Mayo Clinic

European Journal of Heart Failure | January 17, 2025 | Volume: 27 | Issue: 12 | Pages: 3423-3425

10.1002/ejhf.3571 | PMID 39823253 Get It

Prevalence, aetiology, and outcomes of native pulmonary regurgitation in the general adult population
Naser, Jwan A. , Ibrahim, Hossam, Andi, Kartik, Scott, Christopher G. , Pellikka, Patricia A. , Kennedy, Austin M , Connolly, Heidi M. , Nkomo, Vuyisile T. , Warnes, Carole A. , Jain, C. Charles , Egbe, Alexander C. , Andi, Kartik , Jain, Charles C, Borlaug, Barry A , Nkomo, Vuyisile T , Scott, Christopher , Pellikka, Patricia A , Enriquez-Sarano, Maurice , Kennedy, Austin M , Naser, Jwan A , Enriquez‐Sarano, Maurice , Pislaru, Sorin V. , Borlaug, Barry A.

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | January 10, 2025 | Volume: 26 | Issue: 4 | Pages: 695-702

10.1093/ehjci/jeaf011 | PMID 39792481 Get It

Abstract Aims Pulmonary regurgitation (PR) after reparative intervention for congenital heart disease has been studied extensively. However, the burden, distribution of causes, and outcome of PR in adults is unknown. The study aimed to evaluate the prevalence, types, and outcomes of moderate/severe PR in adults in the community setting. Methods and results A total of 398 adult residents of Olmsted County who had clinically indicated echocardiography 2004–2023 at Mayo Clinic, Rochester, and had moderate or severe PR were identified retrospectively. The median age was 77 years, 48% were females, and 61 (51%) had severe PR. The age- and sex-adjusted US prevalence was 0.11% (vs. 0.67% for ≥moderate tricuspid regurgitation). Moderate/severe PR was due to pulmonary hypertension in 77%, congenital/iatrogenic in 11%, primary pulmonary valve disease in 2% (88% due to carcinoid), and idiopathic isolated in 10%. In contrast, severe PR was due to congenital/iatrogenic disease in 52%, pulmonary hypertension in 39%, primary PR in 5%, and isolated idiopathic in 3%. The all-cause mortality rate per 100 person-year was 73 in primary (mostly carcinoid) PR, 16 in pulmonary hypertension–related PR (not different vs. propensity-matched patients without PR), and 6 in isolated idiopathic PR (not different vs. matched patients without PR). Conclusion Moderate or severe PR had a lower prevalence vs. TR. The most frequent cause was pulmonary hypertension for ≥moderate PR and congenital/iatrogenic for severe PR. Mortality in patients with acquired ≥moderate PR appeared to be related to the underlying cause, with no excess mortality compared with matched patients without PR. Whether specifically severe PR confers excess mortality requires future investigation.
Amyloidosis and Heart Transplantation in a New Era
Lyle, Melissa , Wiedmeier-Nutor, Erin J, Lindpere, Vanda , Klanderman, Molly , Nativi-Nicolau, José , Leoni, Juan , Goswami, Rohan , Yip, Daniel , Patel, Parag C. , Sher, Taimur , Rosenbaum, Andrew , AbouEzzeddine, Omar F. , Boilson, Barry A. , Kushwaha, Sudhir S. , Clavell, Alfredo L. , Steidley, D. Eric , Hardaway, Brian , Scott, Robert L. , LeMond, Lisa , Grogan, Martha, Rosenthal, Julie , Lyle, Melissa A , Farina, Juan Maria M, Wiedmeier-Nutor, Erin, Lindpere, Vanda , Nativi-Nicolau, Jose N, Leoni Moreno, Juan Carlos, Goswami, Rohan M , Rosenbaum, Andrew N , Steidley, David E, Hardaway, Brian W, Rosenthal, Julie L , AbouEzzeddine, Omar F , Farina, Juan M. , Leoni, Juan Carlos , Fonseca, Rafaël , Gertz, Morie A. , Dispenzieri, Angela , Grogan, Martha

Mayo Clinic

Clinical Transplantation | January 8, 2025 | Volume: 39 | Issue: 1 | Pages: No page available

10.1111/ctr.70070 | PMID 39775986 Get It

AbstractBackgroundThe prognosis in patients with advanced cardiac amyloidosis (CA) remains poor.ObjectivesWe sought to describe survival post heart transplantation (HT) in amyloid compared with non‐amyloid recipients, highlight waitlist times within the new allocation system across three Organ Procurement and Transplantation Network (OPTN) regions, and describe multiorgan transplantation (MOT) in hereditary amyloidosis.MethodsThis is a retrospective review of end‐stage CA patients who underwent HT at Mayo Clinic from January 2007 to December 2020. Wait time was compared in the new versus old OPTN allocation era starting December 18, 2018 by Wilcoxon rank sum test. All‐cause mortality for those with and without CA was compared using Kaplan–Meier estimates with log rank analysis, censoring December 16, 2022.ResultsFifty‐five patients with CA underwent HT between 2007 and 2020, 8 light chain amyloidosis (AL) (14.5%), 28 hereditary transthyretin (ATTRv) (50.9%), 17 wildtype transthyretin (ATTRwt) (30.9%), and 2 hereditary apolipoprotein A1 (AApoA1) amyloidosis patients (3.6%). No significant difference in overall survival post‐transplant was seen in amyloid compared with non‐amyloid (p = 0.816). Median time to HT was shorter in the new system, 45 days (IQR 24, 78) versus 174 days (IQR 76.5, 483.5), p = 0.006. There was a decline in MOT in hereditary amyloidosis over time with the concomitant rise in disease‐targeted therapies.ConclusionsHT survival in CA patients was similar to non‐amyloid patients. The new allocation system benefits this cohort with shorter wait times. There is less MOT in hereditary amyloidosis with increased utilization of disease‐targeted therapy.
A Comprehensive Review of Artificial Intelligence (AI) Applications in Pulmonary Hypertension (PH)
Esfahani, Sogol Attaripour , Ali, Nima Baba , Farina, Juan M. , Scalia, Isabel G. , Pereyra, Milagros , Abbas, Mohammed Tiseer , Javadi, Niloofar , Bismee, Nadera N. , Abdelfattah, Fatmaelzahraa E., Ibrahim, Omar , Sheashaa, Hesham, Barry, Timothy , Scott, Robert L. , Ayoub, Chadi , Arsanjani, Reza , Attaripour Esfahani, Sogol, Baba Ali, Nima , Awad, Kamal , Ibrahim, Omar H , Sheashaa, Hesham , Barry, Timothy , Arsanjani, Reza , Farina, Juan M , Pereyra, Milagros , Scalia, Isabel G , Abbas, Mohammed Tiseer , Abdelfattah, Fatmaelzahraa , Awad, Kamal

Mayo Clinic

Medicina | January 7, 2025 | Volume: 61 | Issue: 1 | Pages: 85

10.3390/medicina61010085 | PMID 39859065 Get It

Background: Pulmonary hypertension (PH) is a complex condition associated with significant morbidity and mortality. Traditional diagnostic and management approaches for PH often face limitations, leading to delays in diagnosis and potentially suboptimal treatment outcomes. Artificial intelligence (AI), encompassing machine learning (ML) and deep learning (DL) offers a transformative approach to PH care. Materials and Methods: We systematically searched PubMed, Scopus, and Web of Science for original studies on AI applications in PH, using predefined keywords. Out of more than 500 initial articles, 45 relevant studies were selected. Risk of bias was evaluated using PROBAST (Prediction model Risk of Bias Assessment Tool). Results: This review examines the potential applications of AI in PH, focusing on its role in enhancing diagnosis, disease classification, and prognostication. We discuss how AI-powered analysis of medical data can improve the accuracy and efficiency of detecting PH. Furthermore, we explore the potential of AI in risk stratification, leading to treatment optimization for PH. Conclusions: While acknowledging the existing challenges and limitations and the need for continued exploration and refinement of AI-driven tools, this review highlights the significant promise of AI in revolutionizing PH management to improve patient outcomes.
Baseline Kidney Function and the Effects of Dapagliflozin On Health Status in Heart Failure in DEFINE-HF and PRESERVED-HF
Ambrosy, Andrew P. , Patel, Shachi, Windsor, Sheryl L. , Husain, Mansoor, Inzucchi, Silvio E. , Kitzman, Dalane W, Kosiborod, Mikhail , Sauer, Andrew J , Borlaug, Barry A. , Kitzman, Dalane W. , McGuire, Darren K. , Shah, Sanjiv J , Sharma, Kavita, Umpierrez, Guillermo E.

Mayo Clinic

ESC Heart Failure | December 24, 2024 | Volume: 12 | Issue: 3 | Pages: 1676-1681

10.1002/ehf2.15184 | PMID 39716939 Get It

Abstract Aims Sodium–glucose co-transporter-2 (SGLT2) inhibitors improve health status and outcomes in the setting of heart failure (HF) across the range of ejection fraction (EF). Baseline kidney disease is common in HF, complicates HF management and is strongly linked to worse health status. This study aimed to assess whether the treatment effects of dapagliflozin on health status vary based on estimated glomerular filtration rate (eGFR). Methods and Results We conducted a pooled participant-level analysis of two double-blind, randomized trials, DEFINE-HF (n = 236) and PRESERVED-HF (n = 324), which evaluated dapagliflozin versus placebo. Both multicentre studies enrolled adults with HF, New York Heart Association Class II or higher, elevated natriuretic peptides, and an EF &lt; 40% in DEFINE-HF or &gt;45% in PRESERVED-HF. The primary exposure was eGFR. The main outcome was the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) at 12 weeks. Across both trials, there were 583 (99.3%) participants with a baseline eGFR. The median (25th, 75th) eGFR was 59 (46, 77) mL/min/1.73 m2. Dapagliflozin improved KCCQ-CSS at 12 weeks [placebo-adjusted difference, +5.0 points, 95% confidence interval (CI) 2.6–7.5; P &lt; 0.001], and this was consistent in participants with an eGFR ≥ 60 (+6.0 points, 95% CI 2.4–9.7; P = 0.001) and eGFR &lt; 60 (+4.1 points, 95% CI 0.5–7.7; P = 0.025) (P interaction = 0.46). The benefits of dapagliflozin on KCCQ-CSS remained robust across eGFR when modelled as a continuous variable (P interaction = 0.48). Conclusions Dapagliflozin led to early and clinically meaningful improvements in health status in HF patients, regardless of EF or baseline eGFR.
Alterations in Mitochondrial Function in Pulmonary Vascular Diseases
Farha, Samar , Asosingh, Kewal, Comhair, Suzy, Reichard, Andrew, Wanner, Nicholas , Radeva, Milena , Aldred, Micheala A. , Beck, Gerald J. , Finet, J. Emanuel , Grünig, Gabriele , Hill, Nicholas S. , Jellis, Christine , Park, Margaret M., Erzurum, Serpil C. , Group, the PVDOMICS Study, Hassoun, Paul M. , Barnard, John , Rosenzweig, Erika B. , Borlaug, Barry A. , Frantz, Robert P. , Hemnes, Anna R. , Horn, Evelyn M. , Leopold, Jane A. , Mehra, Reena , Rischard, Franz , Tang, W.H. Wilson , Group, the PVDOMICS Study

Mayo Clinic

Antioxidants & Redox Signaling | December 10, 2024 | Volume: 42 | Issue: 7-9 | Pages: 361-377

10.1089/ars.2024.0557 | PMID 39655485 Get It

Aims: Alterations of mitochondrial bioenergetics and arginine metabolism are universally present and mechanistically linked to pulmonary arterial hypertension (PAH), but there is little knowledge of arginine metabolism and mitochondrial functions across the different pulmonary hypertension (PH) groups. We hypothesize that abnormalities in mitochondrial functions are present across all PH groups and associated with clinical phenotypes. We test the hypothesis in PH patients and healthy controls from the Pulmonary Vascular Disease Phenomics Program cohort, who had comprehensive clinical phenotyping and follow-up for at least 4 years for death or transplant status. Mitochondrial transmembrane potential, superoxide production, and mass were measured by flow cytometry in fresh platelets. Metabolomics analysis was performed on plasma samples. Global arginine bioavailability was calculated as the ratio of arginine/(ornithine+citrulline). Results: Global arginine bioavailability is consistently lower than controls in all PH groups. Although the mitochondrial mass is similar across all PH groups and controls, superoxide production and transmembrane potential vary across groups. Mitochondrial superoxide is higher in group 1 PAH and lowest in group 3 compared with other groups, while transmembrane potential is lower in group 1 PAH than controls or group 3. The alterations in mitochondrial functions of group 1 PAH are associated with changes in fatty acid metabolism. Mitochondrial transmembrane potential in group 1 PAH is associated with transplant-free survival. Conclusion: While alterations in mitochondrial function are found in all PH groups, group 1 PAH has a unique mitochondrial phenotype with greater superoxide and lower transmembrane potential linked to fatty acid metabolism, and clinically to survival. Antioxid. Redox Signal. 42, 361–377.
Aerobic Capacity of Adults With Fontan Palliation: Disease-Specific Reference Values and Relationship to Outcomes
Egbe, Alexander C. , Ali, Ahmed E. , Miranda, William R. , Connolly, Heidi M. , Borlaug, Barry A. , Borlaug, Barry A

Mayo Clinic

Circulation: Heart Failure | December 9, 2024 | Volume: 18 | Issue: 2 | Pages: No page available

10.1161/circheartfailure.124.011981 | PMID 39648896 Get It

BACKGROUND: Patients with Fontan palliation have reduced aerobic capacity because of impaired cardiac, pulmonary, and skeletal muscle function. However, the assessment of aerobic capacity in this population still relies on comparisons with people without cardiovascular disease rather than comparison with the expected aerobic capacity of other Fontan patients. The purpose of this study was to determine the expected aerobic capacity of adults with Fontan palliation. METHODS: Adults with Fontan palliation who underwent a cardiopulmonary exercise test at Mayo Clinic (2003–2023) were stratified into quartiles based on the predicted peak oxygen consumption (VO 2 ). We assessed the correlates of predicted peak VO 2 and the relationship between predicted peak VO 2 quartiles and cardiovascular outcomes (death/transplant). RESULTS: Of 323 patients (age, 29±9 years; 177 [55%] men), the median peak VO 2 was 19.1 (15.2–23.9) mL/kg per minute, and this corresponds to a predicted peak VO 2 of 51% (range, 19–88; interquartile range, 41–62). After multivariable adjustments, the correlates of predicted peak VO 2 were body mass index (β±SE, −2.61±0.95; 2.61% decrease in predicted peak VO 2 per 5 kg/m 2 increase in body mass index; P =0.009), systemic saturation (β±SE, 3.65±0.85; 3.65% increase in predicted peak VO 2 per 5% increase in oxygen saturation; P <0.001), and Fontan pressure (β±SE, −1.24±0.22; 1.24% decrease in predicted peak VO 2 per 1 mm Hg increase in Fontan pressures; P <0.001). There was a 47% increase in the risk for death/transplant from a higher predicted peak VO 2 quartile to the next lower quartile (adjusted hazard ratio, 1.47 [95% CI, 1.09–2.05]; P =0.01). CONCLUSIONS: The results of the current study would help calibrate the interpretation of exercise test data in adults with Fontan palliation and improve risk stratification in this population. It also underscores the need to maintain normal Fontan hemodynamics and body weight, which are important determinants of aerobic capacity.